GlassScriptPhysician profile
Herbert M Juarbe
NPI 1437242567
$5,899.74
in general payments reported to CMS, 2019-2025
22 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,307 · 2020: $429 · 2021: $236 · 2022: $2,221 · 2023: $416 · 2024: $631 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,847.52 | 2021-2025 | Minimed 780g |
| Lilly USA, LLC | $1,513.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $919.36 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $373.68 | 2022-2025 | |
| Abbvie INC. | $176.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.50 | 2019-2021 | |
| Insulet Corporation | $158.53 | 2020-2025 | Omnipod |
| Shire North American Group INC | $128.05 | 2019 | |
| Corcept Therapeutics | $108.74 | 2019 | |
| Tandem Diabetes Care, INC. | $105.33 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $103.60 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $61.70 | 2019-2021 | |
| Lifescan, INC. | $46.44 | 2020-2021 | |
| Dexcom, INC. | $32.18 | 2025 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $24.15 | 2025 | Twiist |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.73 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $23.33 | 2021 | |
| Cequr Corporation | $23.30 | 2024 | Cequr Simplicity |
| Abbott Laboratories | $22.01 | 2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $19.04 | 2024 | |
| Medtronic Minimed, INC. | $16.50 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Juarbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.